Marcus Schmidt

20.8k total citations · 3 hit papers
297 papers, 9.0k citations indexed

About

Marcus Schmidt is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marcus Schmidt has authored 297 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 177 papers in Oncology, 102 papers in Cancer Research and 88 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marcus Schmidt's work include Breast Cancer Treatment Studies (90 papers), HER2/EGFR in Cancer Research (76 papers) and Advanced Breast Cancer Therapies (63 papers). Marcus Schmidt is often cited by papers focused on Breast Cancer Treatment Studies (90 papers), HER2/EGFR in Cancer Research (76 papers) and Advanced Breast Cancer Therapies (63 papers). Marcus Schmidt collaborates with scholars based in Germany, United States and Switzerland. Marcus Schmidt's co-authors include Jan G. Hengstler, Mathias Gehrmann, Johannes Ettl, Tamás Pintér, Katalin Boér, Igor Bondarenko, Dennis J. Slamon, Xin Huang, Richard S. Finn and Ravindranath Patel and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Marcus Schmidt

284 papers receiving 8.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

2014 1.4k citations Marcus Schmidt et al. profile →
The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer

2008 588 citations Marcus Schmidt, Daniel Böhm et al. Cancer Research profile →
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

2009 504 citations Gϋnter von Minckwitz, Marcus Schmidt et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marcus Schmidt Germany	42	5.0k	2.8k	2.7k	2.4k	852	297	9.0k
Carey K. Anders United States	45	5.4k 1.1×	2.8k 1.0×	2.6k 1.0×	2.0k 0.8×	555 0.7×	211	8.7k
Linda T. Vahdat United States	52	7.5k 1.5×	2.1k 0.7×	2.7k 1.0×	3.6k 1.5×	837 1.0×	236	11.5k
Maura N. Dickler United States	47	6.4k 1.3×	3.3k 1.2×	2.8k 1.0×	3.4k 1.4×	426 0.5×	166	10.5k
Rebecca Dent Singapore	44	6.5k 1.3×	2.4k 0.9×	4.1k 1.5×	3.0k 1.2×	1.1k 1.2×	186	10.2k
Francesco Cognetti Italy	46	5.0k 1.0×	2.3k 0.8×	1.7k 0.6×	2.4k 1.0×	454 0.5×	221	8.5k
Elizabeth Claire Dees United States	34	4.5k 0.9×	1.4k 0.5×	2.9k 1.1×	3.0k 1.2×	797 0.9×	127	7.9k
William D. Figg United States	52	3.1k 0.6×	3.8k 1.3×	2.4k 0.9×	4.6k 1.9×	625 0.7×	234	10.3k
Ling‐Ming Tseng Taiwan	43	4.9k 1.0×	1.6k 0.6×	3.0k 1.1×	3.6k 1.5×	521 0.6×	228	8.8k
Mariano Provencio Spain	47	4.3k 0.9×	3.3k 1.2×	2.5k 0.9×	3.3k 1.4×	702 0.8×	468	9.1k
Siqing Fu United States	51	4.1k 0.8×	2.4k 0.8×	2.4k 0.9×	3.8k 1.6×	954 1.1×	412	9.6k

Countries citing papers authored by Marcus Schmidt

Since Specialization

Citations

This map shows the geographic impact of Marcus Schmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcus Schmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcus Schmidt more than expected).

Fields of papers citing papers by Marcus Schmidt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcus Schmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcus Schmidt. The network helps show where Marcus Schmidt may publish in the future.

Co-authorship network of co-authors of Marcus Schmidt

This figure shows the co-authorship network connecting the top 25 collaborators of Marcus Schmidt. A scholar is included among the top collaborators of Marcus Schmidt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcus Schmidt. Marcus Schmidt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lohmayer, Regina, Lara Frommherz, Ludger Brühl, et al.. (2025). Overview of the nutrient composition of selected milling products from rye, spelt and wheat in Germany. Journal of Food Composition and Analysis. 140. 107275–107275. 2 indexed citations

Ormeci, Alim, Yurii Prots, Matej Bobnar, et al.. (2025). Slab Rotation by Transition‐Metal Relocation in the Layered Zintl Phase Li₂ZnSi. European Journal of Inorganic Chemistry. 28(27). 1 indexed citations

Brühl, Ludger, Ralf Greiner, Alexandra Hüsken, et al.. (2024). Characterization of the nutritional profile of three plant-based drinks. Journal of Food Composition and Analysis. 135. 106553–106553. 6 indexed citations

Weide, Rudolf, et al.. (2024). Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care. Cancers. 16(7). 1255–1255. 1 indexed citations

Schröder, Maria, Valerie Catherine Linz, Slavomir Krajnak, et al.. (2024). Occurrence and Management of Immunotherapy-Associated Adverse Events in Patients with Gynecological Cancers. Cancers. 16(7). 1371–1371. 2 indexed citations

Almstedt, Katrin, Franziska Kappenberg, Daniel‐Christoph Wagner, et al.. (2023). Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer. Cancers. 15(5). 1413–1413. 20 indexed citations

Thomssen, Christoph, Martina Vetter, Eva Johanna Kantelhardt, et al.. (2023). Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group. Cancers. 15(5). 1580–1580.

Schmidt, Marcus, Ulrike Nitz, Toralf Reimer, et al.. (2023). Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate – The ICE randomized clinical trial. European Journal of Cancer. 194. 113324–113324. 1 indexed citations

Almstedt, Katrin, Anne-Sophie Heimes, Franziska Kappenberg, et al.. (2022). Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. European Journal of Cancer. 173. 10–19. 60 indexed citations

10.

Moehler, Markus, et al.. (2021). Any progress in informed consenting for cancer treatment? Results from a cross sectional analysis at a comprehensive cancer center. Journal of Cancer Research and Clinical Oncology. 147(7). 2117–2126. 6 indexed citations

11.

Krajnak, Slavomir, Katrin Almstedt, Walburgis Brenner, et al.. (2020). Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study. Breast Cancer Research and Treatment. 182(2). 389–399. 14 indexed citations

12.

Lebeau, Annette, Carsten Denkert, Hans‐Peter Sinn, Marcus Schmidt, & Achim Wöckel. (2019). Update der S3-Leitlinie Mammakarzinom: Was gibt es Neues für Pathologen?. Der Pathologe. 40(2). 185–198. 1 indexed citations

13.

Schneeweiß, Andreas, Frank Förster, Hans Tesch, et al.. (2016). First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.. PubMed. 36(3). 967–74. 10 indexed citations

14.

Edlund, Karolina, Marianna Grinberg, Seddik Hammad, et al.. (2015). Gelsolin Is Associated with Longer Metastasis-free Survival and Reduced Cell Migration in Estrogen Receptor-positive Breast Cancer.. PubMed. 35(10). 5277–85. 16 indexed citations

15.

Schmidt, Wolfgang, et al.. (2015). Synopse der Hauptmerkmale der forstlichen Standortskartierungsverfahren der Nordwestdeutschen Bundesländer. GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen). 4 indexed citations

16.

Brase, Jan C., Marcus Schmidt, Thomas Fischbach, et al.. (2010). ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction. Clinical Cancer Research. 16(8). 2391–2401. 108 indexed citations

17.

Schmidt, Marcus, Mathias Gehrmann, Jan G. Hengstler, & Heinz Koelbl. (2010). New prognostic and predictive factors in breast cancer.. PubMed. 62(6). 599–611. 6 indexed citations

18.

Schmidt, Marcus, Jan G. Hengstler, Christian von Törne, Heinz Koelbl, & Mathias Gehrmann. (2009). Coordinates in the Universe of Node-Negative Breast Cancer Revisited. Cancer Research. 69(7). 2695–2698. 28 indexed citations

19.

Schmidt, Marcus, Daniel Böhm, Christian von Törne, et al.. (2008). The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer. Cancer Research. 68(13). 5405–5413. 588 indexed citations breakdown →

20.

Schmidt, Marcus, Dirk Hasenclever, Daniel Boehm, et al.. (2008). Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer. Clinical Cancer Research. 14(18). 5849–5855. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact